Rubella, also known as German measles, is a contagious viral infection best known for its characteristic red rash. Although often mild in children and young adults, rubella poses serious risks to pregnant women and their unborn babies. The history of rubella, its clinical progression, and the global response to managing and eradicating it through vaccination and public health measures form a fascinating chapter in medical science.
Rubella was first clinically described as a distinct disease in the 18th century, although its symptoms were likely confused with measles or scarlet fever for centuries. German physicians Friedrich Hoffmann, de Bergen, and Orlow were among the first to document rubella in the mid-1700s, which is why it was often referred to as “German measles.”
It was not until 1881 that the International Congress of Medicine officially recognised rubella as a disease distinct from measles and scarlet fever. The virus responsible for rubella was eventually isolated in 1962 by a team of virologists led by Thomas Weller. This discovery paved the way for vaccine development and the modern public health approach to the disease.
A turning point in the history of rubella occurred during the global rubella pandemic of 1962–1965, particularly in the United States. An estimated 12.5 million cases occurred, resulting in 11,000 foetal deaths and thousands of babies born with congenital rubella syndrome (CRS)—a condition causing deafness, heart defects, cataracts, and developmental delays. This tragic outcome highlighted the urgent need for a vaccine and gave rubella a prominent place in global health priorities.
Transmission and symptoms
Rubella is caused by the rubella virus, a member of the Togaviridae family, and spreads through respiratory droplets when an infected person coughs or sneezes. The incubation period is typically 14–21 days, and individuals are most contagious from a few days before the rash appears until about a week afterward.
Symptoms are usually mild, especially in children. The most common signs include a low-grade fever, swollen lymph nodes (particularly behind the ears), a fine pink rash that starts on the face and spreads to the body, and joint pain, which is more common in adults, especially women. Because the symptoms can resemble other viral illnesses or be completely absent, asymptomatic cases are common—rubella can spread undetected, posing a particular threat to unvaccinated pregnant women.
The most serious consequences of rubella infection occur when a woman contracts the virus during pregnancy, especially in the first trimester. The rubella virus can cross the placenta and infect the foetus, leading to miscarriage, stillbirth, or a range of birth defects collectively known as congenital rubella syndrome (CRS).
CRS can affect nearly every organ system and is a leading cause of preventable congenital anomalies when rubella is not controlled. Common complications include hearing impairment or deafness, cataracts and other eye abnormalities, congenital heart defects, intellectual disabilities and developmental delays, and liver and spleen damage. Due to the severe and lifelong impact of CRS, preventing maternal rubella infection has been a central goal of vaccination programs worldwide.
Diagnosis, management and prevention
Rubella is usually diagnosed based on clinical symptoms, particularly during outbreaks. However, laboratory confirmation is often required because of the nonspecific nature of the symptoms. Diagnostic methods include rubella-specific IgM antibody tests, PCR (polymerase chain reaction) to detect viral RNA, and prenatal testing for suspected CRS cases.
There is no specific antiviral treatment for rubella. Management focuses on relieving symptoms such as rest, hydration, and fever reduction. CRS, however, may require long-term care from a multidisciplinary team to address various congenital abnormalities.
The first rubella vaccine was licenced in the United States in 1969. Today, the rubella vaccine is typically combined with the measles and mumps vaccines in the MMR (measles, mumps, rubella) formulation. The MMR vaccine is highly effective; two doses confer about 97 per cent protection against rubella.
Widespread immunisation programmes have dramatically reduced rubella incidence worldwide. For example, the Americas region was declared free of endemic rubella transmission in 2015 after years of intensive vaccination efforts. Similar successes have been reported in parts of Europe and the Western Pacific. However, rubella remains endemic in some regions of Africa and Southeast Asia, where immunisation coverage is still low.
The World Health Organisation (WHO) aims to eliminate rubella and CRS globally through sustained vaccination and surveillance. Strategies include including MMR in national immunisation schedules, conducting mass vaccination campaigns, monitoring and investigating suspected cases, and ensuring immunity among women of childbearing age.
Rubella has evolved from a misunderstood childhood rash to a globally recognised public health threat, especially because of its devastating impact on unborn children. The introduction of an effective vaccine transformed rubella from a widespread viral illness to one that is now rare in many parts of the world.
Despite these achievements, challenges remain. Incomplete immunisation coverage, misinformation, and healthcare access disparities continue to allow rubella to circulate in some regions.
